343 related articles for article (PubMed ID: 27080842)
1. The contribution of pharmacogenetics to pharmacovigilance.
Bondon-Guitton E; Despas F; Becquemont L
Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of drug hypersensitivity.
Phillips EJ; Mallal SA
Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM; Everts RE; Aggarwal P; Beyer BN; Broeckel U; Epstein-Baak R; Hujsak P; Kornreich R; Liao J; Lorier R; Scott SA; Smith CH; Toji LH; Turner A; Kalman LV
J Mol Diagn; 2016 Jan; 18(1):109-23. PubMed ID: 26621101
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.
Dervieux T; Meshkin B; Neri B
Mutat Res; 2005 Jun; 573(1-2):180-94. PubMed ID: 15829247
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
Becquemont L
Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
Sim SC; Kacevska M; Ingelman-Sundberg M
Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
[TBL] [Abstract][Full Text] [Related]
8. HLA alleles and drug hypersensitivity reactions.
Profaizer T; Eckels D
Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics: The right drug for you.
Drew L
Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
[No Abstract] [Full Text] [Related]
11. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity.
Guéant JL; Guéant-Rodriguez RM; Gastin IA; Cornejo-García JA; Viola M; Barbaud A; Mertes PM; Blanca M; Romano A
Curr Pharm Des; 2008; 14(27):2770-7. PubMed ID: 18991696
[TBL] [Abstract][Full Text] [Related]
12. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics: from bench to byte--an update of guidelines.
Swen JJ; Nijenhuis M; de Boer A; Grandia L; Maitland-van der Zee AH; Mulder H; Rongen GA; van Schaik RH; Schalekamp T; Touw DJ; van der Weide J; Wilffert B; Deneer VH; Guchelaar HJ
Clin Pharmacol Ther; 2011 May; 89(5):662-73. PubMed ID: 21412232
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future.
Alfirevic A; Pirmohamed M
Pharmacogenomics; 2010 Apr; 11(4):497-9. PubMed ID: 20350129
[TBL] [Abstract][Full Text] [Related]
15. Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil.
Camargo AC; Matte U; Botton MR
Expert Opin Drug Saf; 2023; 22(7):621-627. PubMed ID: 36794346
[TBL] [Abstract][Full Text] [Related]
16. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
Nolan D
Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
[TBL] [Abstract][Full Text] [Related]
17. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
18. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
[TBL] [Abstract][Full Text] [Related]
19. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
[TBL] [Abstract][Full Text] [Related]
20. [Importance of HLA in Determining Individual Differences in the Onset of Adverse Drug Reactions].
Aoki S
Yakugaku Zasshi; 2021; 141(8):1001-1007. PubMed ID: 34334545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
